Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes

European Journal of Clinical Pharmacology

Volumn 60, Issue 8, 2004, Pages 575-581

  Kim, Kyoung Ah ^a   Chung, Jaegul ^a   Jung, Dong Hae ^a   Park, Ji Young ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

CYP2C8; CYP3A4; Cytochrome P450 (P450); Human liver microsomes; Loperamide

Indexed keywords

7 ETHOXY 4 TRIFLUOROMETHYLCOUMARIN; ALPHA HYDROXYMIDAZOLAM; COMPLEMENTARY DNA; COUMARIN; COUMARIN DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FURAFYLLINE; ISOPROTEIN; KETOCONAZOLE; LOPERAMIDE; MIDAZOLAM; NORLOPERAMIDE; OMEPRAZOLE; ORPHENADRINE; PACLITAXEL; QUERCETIN; QUINIDINE; SULFAPHENAZOLE; UNCLASSIFIED DRUG; ZALCITABINE;

ARTICLE; CATALYSIS; CORRELATION ANALYSIS; DEMETHYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTIDIARRHEALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; LOPERAMIDE; MICROSOMES, LIVER;

EID: 8744278943     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0815-3     Document Type: Article

References (36)

1. Camilleri M (1998) Therapeutic approach to the patient with irritable bowel syndrome. Am J Med 107:27S-32S
2. Sach JA, Chang L (2002) Irritable bowel syndrome. Curr Treat Options Gastroenterol 5:267-278
3. Fogel R (2001) Fecal incontinence. Curr Treat Options Gastroenterol 4:261-266
4. Schiller LR (2003) Treatment of fecal incontinence. Curr Treat Options Gastroenterol 6:319-327
5. De Haven-Hudkins DL, Cowan A, Cortes Burgos L, Daubert JD, Cassel JA, DeHaven RN, Kehner GB, Kumar V, Park-Wyllie LY, Antoniou T (2002) Antipruritic and antihyperalgesic actions of loperamide and analogs. Life Sci 71:2787-2796
6. De Haven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, Yaksh T (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289:494-502
7. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996) P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97:2517-2524
8. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ (2000) Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 68:231-237
9. Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM, Gjellan K (2001) Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214
10. Wandel C, Kim R, Wood M, Wood A (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920
11. Miyazaki H, Nambu K, Matsunaga Y, Hashimoto M (1979) Disposition and metabolism of [14C]loperamide in rats. Eur J Drug Metab Pharmacokinet. 4:199-206
12. Yoshida K, Nambu K, Arakawa S, Miyazaki H, Hashimoto M (1979) Metabolites of loperamide in rats. Biomed Mass Spectrom 6:253-259
13. He H, Sadeque A, Erve JC, Wood AJ, Hachey DL (2000) Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 744:323-331
14. Tayrouz Y, Ganssmann B, Ding R, Klingmann A, Aderjan R, Burhenne J, Haefeli WE, Mikus G (2001) Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clin Pharmacol Ther 70:405-414
15. Park JY, Kim KA, Kim SL (2003) Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother 47:3464-3469
16. Kim KA, Park JY (2003) Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes. Drug Metab Dispos 31:1090-1092
17. Park JY, Kim KA (2003) Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes. Eur J Clin Pharmacol 59:407-409
18. Eagling VA, Tjia JF, Back DJ (1998) Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-114
19. Pearce R, Greenway D, Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P4502A enzymes: effect on coumarin, dicumarol and testosterone oxidation. Arch Biochem Biophys 298:211-225
20. Kobayashi K, Abe S, Nakajima M, Shimada N, Tani M, Chiba K, Yamamoto T (1999) Role of human CYP2B6 in S-mephobarbital N-demethylation. Drug Metab Dispos 27:1429-1433
21. Rahman A, Korzekwa KR, Grogan J, Gonzales FJ, Harris JW (1994) Selective biotransformation of Taxol to 6-alpha hydroxy Taxol by human cytochrome P450 2C8. Cancer Res 54:5543-5546
22. Newton DJ, Wang RW, Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158
23. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862
24. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381-1391
25. Stormer E, von Moltke LL, Greenblatt DJ (2000) Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295:793-801
26. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504
27. Rochat B (2003) Evaluation of recombinant cytochromes P450 activity in metabolic pathways. Drug Metab Dispos 31:145-146
28. Crespi CL (1995) Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235
29. Venkatakrishnan K, von Moltke LL, Greenblatt DJ (1998) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high-affinity component as an index of CYP1A2 activity. J Pharm Sci 87:1502-1507
30. Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853-858
31. Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase I, Tanaka K, Funae Y, Ishizaki T, Asada A (2001) Involvement of human liver cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol 51:281-285
32. Sai Y, Dai R, Yang TJ, Krausz KW, Gonzalez FJ, Gelboin HV, Shou M (2000) Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30:327-343
33. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908
34. Park-Wyllie LY, Antoniou T (2003) Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. AIDS 17:638-640
35. Kim KA, Park JY, Lee JS, Lim S (2003) Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 26:631-637
36. Stormer E, Brockmoller J, Roots I, Schmider J (2000) Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology 151:312-320